Publikationen

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.

Eckardt JN, Röllig C, Metzeler K, Kramer M, Stasik S, Georgi JA, Heisig P, Spiekermann K, Krug U, Braess J, Görlich D, Sauerland CM, Woermann B, Herold T, Berdel WE, Hiddemann W, Kroschinsky F, Schetelig J, Platzbecker U, Müller-Tidow C, Sauer T, Serve H, Baldus C, Schäfer-Eckart K, Kaufmann M, Krause S, Hänel M, Schliemann C, Hanoun M, Thiede C, Bornhäuser M, Wendt K, Middeke JM.

Haematologica 2022 Jun 16. doi: 10.3324/haematol.2021.280027.

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.

Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, Schäfer-Eckart K, Burgues JMB, Steffen B, Bernal T, Krause SW, Riaza R, Schliemann C, Cervera J, Kaufmann M, Torres-Miñana L, Hänel M, Acuña-Cruz E, Jost E, Algarra JL, Crysandt M, Fransecky L, Cornago- Navascues J, Kraus S, Martinez-Lopez J, Einsele H, Niemann D, Neubauer A, Seggewiß-Bernhardt R, Scholl S, Klein SA, Schmid C, Schaich M, Schmidt-Hieber M, Zukunft S, Ho AD, Platzbecker U, Baldus CD, Müller-Tidow C, Thiede C, Bornhäuser M, Serve H, Levis M, Montesinos P, Röllig C, Schlenk RF.

Haematologica 2022 Jun 9. doi: 10.3324/haematol.2022.281137.
 

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.

Eckardt JN, Stölzel F, Kunadt D, Röllig C, Stasik S, Wagenführ L, Jöhrens K, Kuithan F, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Andreas Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Kroschinsky F, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Schetelig J, Bornhäuser M, Thiede C, Middeke JM.

J Hematol Oncol 2022; 15(1):60.      
 

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S, Hänel M.

J Cancer Res Clin Oncol 2022; 148(5):1171-1181.                                                                    
 

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: Results from a large multicenter study.

Middeke JM, Metzeler KH, Röllig C, Kramer M, Eckardt JN, Stasik S, Greif PA, Spiekermann K, Rothenberg-Thurley M, Krug U, Braess J, Kraemer A, Hochhaus A, Brümmendorf TH, Naumann R, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Görlich D, Sauerland CM, Schaefer-Eckart K, Schliemann C, Krause SW, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Kaufmann M, Kunadt D, Woermann B, Sockel K, von Bonin M, Herold T, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Baldus CD, Ehninger G, Schetelig J, Hiddemann W, Bornhäuser M, Stölzel F, Thiede C.

Blood Adv 2022; 6(5):1394-1405.                                                                                                   
 

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.

Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel KC.

Leukemia 2022; 36(3):885-888.                                                                                                      

Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma.

Jacob AS, Kaul H, Fuchs M, Gillessen S, Kreissl S, Pluetschow A, Momotow J, Schaub V, Huettmann A, Hänel M, Zimmermann A, Dierlamm J, Meissner J, Mathas S, Martin S, Engert A, Hallek M, Borchmann P, Lehmann C.              

Infection 2022; Feb 19:1-8. doi: 10.1007/s15010-022-01765-3.                                        
 

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.

Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M.

Bone Marrow Transplant 2022; 57:499-501.                                                                             
 

CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.

Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, Krämer A, Scholl S, Hochhaus A, Brümmendorf TH, Naumann R, Petzold A, Mulet-Lazaro R, Valk PJM, Steffen B, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW,  Hänel M, Noppeney R, Kaiser U, Baldus C, Kaufmann M, Herold S, Stölzel F, Sockel K, von Bonin M, Müller-Tidow C, Platzbecker U, Berdel WE, Serve H, Ehninger G, Bornhäuser M, Schetelig J, Thiede C.

Blood 2022; 139(1):87-103.                       

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.

Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM.

Blood Cancer J 2021; 11(10):1-8.                                                                                                   

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.

Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, Bertsch U, Hielscher T, Morgan GJ, Jauch A, Davies FE, Hänel M, Cook G, Scheid C, Houlston R, Goldschmidt H, Jackson G, Kaiser MF.

Haematologica 2021; 106(10):2754-2758.      

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.

Stasik S, Eckardt JN, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Middeke JM, Thiede C; Study Alliance Leukemia (SAL).

Blood Adv 2021; 5(17):3279-3289.                                                                                  

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry.

Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M, Pahl HL, Lang F, Kirschner M, Isfort S, Brümmendorf TH, Döhner K, Koschmieder S.

Cancers (Basel) 2021; 13(16):4086.                                                                                 

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.

Hirt C, Hoster E, Unterhalt M, Hänel M, Prange-Krex G, Forstpointner R, Florschütz A, Graeven U, Frickhofen N, Wulf G, Lengfelder E, Lerchenmüller C, Schlag R, Dierlamm J, Fischer von Weikersthal L, Ahmed A, Harich HD, Rosenwald A, Klapper W, Dreyling M, Hiddemann W, Herold M.

Hemasphere 2021; 5(7):e600.                                                                                                         

Case Report: Eighteen Month Relapse- Free Survival Following Radical Multidisciplinary Oncological Treatment in a 68-Year-Old Male Patient With Histiocytic Sarcoma.

Wehrmann S, Rudolph H, Ernst D, Siepmann T, Kaltofen D, Hänel M, Mirow L.

Front Oncol 2021; 11:633215.                                                                                                          

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.

Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, Bertsch U, Hielscher T, Morgan GJ, Jauch A, Davies FE, Hänel M, Cook G, Scheid C, Houlston R, Goldschmidt H, Jackson G, Kaiser MF.

Haematologica 2021; 106(10):2754-2758.                                                                 

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial.

Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Hänel M, Jehn C, Mai EK, Bertsch U, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Raab MS, Luntz SP, Besemer B, Munder M, Brossart P, Fuhrmann S, Lindemann HW, Weisel K, Duerig J, Goldschmidt H.

Leukemia 2021; 35(10):3007-3011.                                                                              

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Hänel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O.

Blood 2021; 137(19):2646-2656.                                                                                                     

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.

Eckardt JN, Stasik S, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Stölzel F, Kroschinsky F, Schetelig J, Bornhäuser M, Thiede C, Middeke JM.

Cancers (Basel) 2021; 13(9):2095.                                                                                   

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase-3 trial.

Frontzek F, Ziepert M, Nickelsen M, Altmann B, Glass B, Hänel M, Truemper L, Held G, Bentz Rosenwald A, Loeffler M, Lenz G, Schmitz N.           

Lancet Haematol 2021; 8(4):e267-e277.                                                                                      

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HS, Goldschmidt H.         

Leukemia 2021; 35(3):809-822.                                                                                                      

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukemia: long-term follow-upof the randomized controlled SORAML trial.

Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Müller-Tidow C, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Frickhofen N, Kullmer J, Kaiser U, Kiani A, Link H, Geer T, Reichle A, Junghanß C, Repp R, Meinhardt A, Dürk H, Klut IM, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Platzbecker U, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia (SAL).           

Leukemia 2021; 35(9):2517-2525.                                                                                  

Selective eleimination of immunosuppressive T cells in patients with multiple myeloma.

Awwad MHS, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, Raab MS, Bertsch U, Munder M, Jauch A, Weisel K, Maier B, Weinhold N, Salwender HJ, Eckstein V, Hänel M, Fenk R, Dürig J, Brors B, Benner A, Müller-Tidow C, Goldschmidt H, Hundemer M.       

Leukemia 2021; 35(9):2602-2615.                                                                                   

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.

Schmitz N, Truemper LH, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner-Drouet EM, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky FP, Lindemann WW, Dreger P, Viardot A, Milpied NJ, Gisselbrecht C, Wulf GG, Gyan E, Gaulard P, Bay  JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer AJ, Bilger K, Banos A, Hänel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O.

Blood 2021; 137(19):2646-2656.                                                                                                       

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age.

Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia 2021; 35(3):809-822.                                                                                                          

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/ dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Hänel M, Martin H,Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG).

Leukemia 2021; 35(4):1134-1135.                                                                                                     

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M, Fuhrmann S, Dührsen U, Brossart P, Neben K, Schlenzka J, Kunz C, Raab MS, Hillengaß J, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Goerner M, Hoffmann M, Lindemann HW, Bernhard H, Blau IW, Scheid C, Besemer B, Weisel KC, Hänel M, Dürig J, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG).

Blood Cancer J 2021; 11(1):1-10.

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment.

Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S and for The German-Speaking Myeloma Multicenter Group (GMMG).

Cancers 2020; 12(8):e2322.                                                                                                                              

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.

Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J.

Blood Adv 2020; 4(13):3093-3101.

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Völker LA, Kaufeld J, Miesbach W, Brähler S, Reinhardt M, Kühne L, Mühlfeld A, Schreiber A, Gaedeke J, Tölle M, Jabs WJ, Özcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gäckler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J.

Blood Adv 2020; 4(13):3085-3092.

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Röllig C, Kramer M, Schliemann C, Mikesch JH, Steffen B, Krämer A, Noppeney R, Schäfer-Eckart K, Krause SW, Hänel M, Herbst R, Kunzmann V, Einsele H, Jost E, Brümmendorf TH, Scholl S, Hochhaus A, Neubauer A, Sohlbach K, Fransecky L, Kaufmann M, Niemann D, Schaich M, Frickhofen N, Kiani A, Heits F, Krümpelmann U, Kaiser U, Kullmer J, Wass M, Stölzel F, von Bonin M, Middeke JM, Thiede C, Schetelig J, Berdel WE, Ehninger G, Baldus CD, Müller-Tidow

C, Platzbecker U, Serve H, Bornhäuser M.

Blood 2020; 136(7):823-830.                                                                                                               

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Hänel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance.

Lancet 2020; 394(10216):2271-2281.                                                                                               

Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.

Shouval R, Labopin M, Bomze D, Baerlocher GM, Capria S, Blaise D, Hänel M, Forcade E, Huynh A, Saccardi R, Milone G, Zuckerman T, Reményi P, Versluis J, Esteve J, Gorin NC, Mohty M, Nagler A.

Bone Marrow Transplant 2020; 55:2244-2253.

EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia.

Stasik S, Middeke JM, Kramer M, Röllig C, Krämer A, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause S, Herbst R, Hänel M, Frickhofen N, Noppeney R, Kaiser U, Baldus CD, Kaufmann M, Rácil Z, Platzbecker U, Berdel WE, Mayer J, Serve H, Müller-Tidow C, Ehninger G, Bornhäuser M, Schetelig J, Thiede C; Study Alliance Leukemia (SAL).

Haematologica 2020; 105(5):e228-e231.                                                                                        

Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.

Davies A, Trask P, Demeter J, Florschütz A, Hänel M, Kinoshita T, Pettengell R, Quach H, Robinson S, Sadullah S, Sancho JM, Udvardy M, Witzens-Harig M, Knapp A, Liu W.

Ann Hematol 2020; 99(12):2837-2846                                                                                            

Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.

Fasslrinner F, Stölzel F, Kramer M, Teipel R, Brogsitter C, Morgner A, Arndt C, Bachmann M, Hänel M, Röllig C, Kotzerke J, Schetelig J, Bornhäuser M.

Biol Blood Marrow Transplant 2020; 26(4):691-697.                                                                  

Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN).

Brioli A, Manz K, Pfirrmann M, Hänel M, Schwarzer AC, Prange-Krex G, Fabisch C, Knop S, Illmer T, Krammer-Steiner B, Hochhaus A, von Lilienfeld-Toal M, Mügge LO.

J Cancer Res Clin Oncol 2020; 146(3):749-759.                                                                             

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hänel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia 2020; 34(3):914-918.                                                                                                          

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.

Goldschmidt H, Mai EK, Dürig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, Hügle-Dörr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Hänel M, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia 2020; 34(7):1853-1865.                                                                                                     

Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.

Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM.

Br J Haematol 2020; 189(5):888-903.

Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.

Kroschinsky F, Röllig D, Riemer B, Kramer M, Ordemann R, Schetelig J, Bornhäuser M, Ehninger G, Hänel M.

J Cancer Res Clin Oncol 2019; 145(12):3067-3073.                                                                      

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol 2019; 144(3):501-509.                                                                                                 

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Hänel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J 2019; 9(9):71.                                                                                                             

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A.

J Hematol Oncol 2019; 12(1):65.                                                                                                        

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Hänel M, Scheid C, Goldschmidt H.

BMC Cancer 2019; 19(1):504.                                                                                                              

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica 2019; 104(5):955-962.                                                                                             

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Hänel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H.

Blood Cancer J 2019; 9(4):45.       

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Hänel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group.

Br J Haematol 2019; 184(5):760-768.                                                                                               

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group.

Br J Haematol 2019; 184(5):833-836.                                                                                               

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J 2019; 9(2):13.

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.

Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S.

Clin Lymphoma Myeloma Leuk 2018; 18(4):266-271. 

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol 2018; 182(6):807-815.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

Platzbecker U, Middeke JM, Sockel K, Herbst R, Wolf D, Baldus CD, Oelschlägel U, Mütherig A, Fransecky L, Noppeney R, Bug G, Götze KS, Krämer A, Bochtler T, Stelljes M, Groth C, Schubert A, Mende M, Stölzel F, Borkmann C, Kubasch AS, von Bonin M, Serve H, Hänel M, Dührsen U, Schetelig J, Röllig C, Kramer M, Ehninger G, Bornhäuser M, Thiede C.

Lancet Oncol 2018; 19(12):1668-1679.                                                                                            

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology 2018; 7(10):e1486356                                                                                      

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol 2018; 144(8):1581-1589.                                                                        

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol 2018; 20(7):975-985.                                                                                                    

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients.

Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler US; Study Alliance Leukemia (SAL).

Ann Oncol 2018; 29(4):973-978.                                                                                                        

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Hänel M, Weisel KC, Goldschmidt H.

Blood Adv 2018; 2(1):1-9.

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML.

Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U.

Leukemia 2017; 31(10):2247-2251.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Mu Ller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Xavier Mahon F, Pfirrmann M, Burchert A.

Leukemia 2017; 31(4):829-836.

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G.

Leukemia. 2017, 31(4):846-852.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.

Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G.

Ann Hematol 2017; 96(9):1463-1470.

Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Bento L, Boumendil A, Finel H, Le Gouill S, Amorim S, Monjanel H, Bouabdallah R, Bay JO, Nicolas-Virelizier E, McQuaker G, Rossi G, Johnson R, Huynh A, Ceballos P, Rambaldi A, Bachy E, Malladi R, Orchard K, Pohlreich D, Tilly H, Bonifazi F, Poiré X, Guilhot F, Haenel A, Crawley C, Metzner B, Gribben J, Russell NH, Damaj G, Thomson K, Dreger P, Montoto S.

Bone Marrow Transplant 2017; 52(8):1120-1125.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia 2017; 31(11):2398-2406.                                                                                                   

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C.

Br J Haematol 2017; 179(3):410-420.                                                                                               

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol 2017; 28(11):2793-2798.                                                                                                 

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant 2017; 23(9):1491-1497.                                                             

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Hänel M, Weisel K, Goldschmidt H, Hillengass J.

Haematologica 2017; 102(8):1432-1438.                                                                                        

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant 2017; 52(8):1194-1198.                                                                       

Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Hänel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P.

Eur J Haematol 2017; 99(1):42-50.                                                                                                    

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F.

J Clin Oncol 2017; 35(6):605-612.                                                                                                     

Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).

Wermke M, Schuster C, Nolte F, Al-Ali HK, Kiewe P, Schönefeldt C, Jakob C, von Bonin M, Hentschel L, Klut IM, Ehninger G, Bornhäuser M, Baretton G, Germing U, Herbst R, Haase D, Hofmann WK, Platzbecker U.

Br J Haematol 2016, 175(5):917-924

Long-term follow-up of patients with relapsed or refractory non-Hodgkin's lymphoma receiving allogeneic stem cell transplantation.

Link CS, Mies F, Scheele J, Kramer M, Schetelig J, Ordemann R, Hänel M, Bornhäuser M, Ehninger G, Kroschinsky F.

Bone Marrow Transplant 2016, 51(11):1527-1529

Increase of T and B cells and altered BACH2 expression patterns in bone marrow trephines of imatinib-treated patients with chronic myelogenous leukaemia.

Von Laffert M, Hänel M, Dietel M, Anagnostopoulos I, Jöhrens K.

Oncol Lett 2016, 12(4):2421-2428.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol 2016, 95(9):1399-1410.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016, 8(49):84847-84862.

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.

Lancet 2016, 388(10044):565-75.

Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.

Mai EK, Benner A, Bertsch U, Brossart P, Hänel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H.

Br J Haematol 2016, 173(5):731-741

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol 2016, 34(14):1611-1619.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

J Hematol Oncol 2016, 9:18.

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL).

Br J Haematol 2016, 172(6):914-922.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant 2016, 22(3):462-469.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia 2016, 30(3):555-561.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Leukemia 2016, 30(2):261-217.

Karyotype complexity and prognosis in acute myeloid leukemia.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G.

Blood Cancer J. 2016, 6:e386.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO).

Kahl C, Krahl R, Becker C, Al-Ali HK, Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D.

J Cancer Res Clin Oncol 2016, 142(1):305-315.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol 2015, 16(16):1691-1699.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R; SAKK and the German CML Study Group.

Ann Hematol 2015, 94(12):2015-2024.

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.

Stöhr E, Schmeel FC, Schmeel LC, Hänel M, Schmidt-Wolf IG; German Refractory Myeloma Study Group.

J Cancer Res Clin Oncol 2015, 141(12):2205-2212.

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).

Thiel A, Schetelig J, Pönisch W, Schäfer-Eckart K, Aulitzky W, Peter N, Schulze A, Maschmeyer G, Neugebauer S, Herbst R, Hänel A, Morgner A, Kroschinsky F, Bornhäuser M, Lange T, Wilhelm M, Niederwieser D, Ehninger G, Fiedler F, Hänel M; East German Study Group Hematology/Oncology (OSHO); Study Alliance Leukemia (SAL).

Ann Oncol 2015, 26(7):1434-1440.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.

Leukemia 2015, 29(5):1060-1068

Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.

Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U.

Ann Hematol 2015, 94(4):557-563

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol 2015, 33(5):403-410.